A team led by US Food and Drug Administration (FDA) researchers studying Medicare claims data during the early Omicron SARS-CoV-2 variant months conclude that a third dose of mRNA COVID-19 vaccine provides significant protection against hospitalization and death compared with two doses but wanes substantially after 4 months.
Respiratory syncytial virus (RSV) remains the top cause of hospitalization among young children, leading to respiratory issues like bronchiolitis and pneumonia. However, the reasons why some children experience only mild symptoms while others suffer from severe disease are not well understood.
Recent Comments